Abstract OBJECTIVE: To assess and compare the effectiveness and safety of methylphenidate immediate-release tablets (IR-MPH), methylphenidate controlled release tablets (OROS-MPH) and atomoxetine (AHC) for attention deficit hyperactivity disorder (ADHD) in Chinese children. METHODS: Randomized or clinical controlled trials on the effectiveness and safety of IR-MPH, OROS-MPH and AHC for ADHD were searched in electronic databases of CNKI, VIP, CBMDISC online, PubMed, Embase and MEDLINE. Two reviewers independently extracted the data and assessed the quality of the included literatures. RESULTS: Eight trials were finally included. IR-MPH, OROS-MPH and AHC were effective for ADHD. OROS-MPH was superior to IR-MPH in the improvement of peer relationship, CGI-I score, mother satisfaction and psychosomatic problems. There were no significant differences in the effectiveness between the AHC and IR-MPH groups. The adverse events related to the therapy with IR-MPH, OROS-MPH or AHC were mild and the incidence rates of adverse events were not significantly different among the three groups. CONCLUSIONS: The effectiveness of OROS-MPH for the treatment of ADHD is probably superior to IR-MPH, and the effectiveness between AHC and IR-MPH is similar. The three drugs demonstrate the safety and well tolerance.
LV, Xiao-Zhen,SHU Zheng,ZHANG Yao-Wen et al. Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review[J]. 中国当代儿科杂志, 2011, 13(5): 365-369.
LV, Xiao-Zhen,SHU Zheng,ZHANG Yao-Wen et al. Effectiveness and safety of methylphenidate and atomoxetine for attention deficit hyperactivity disorder: a systematic review[J]. CJCP, 2011, 13(5): 365-369.
［2］Spencer T, Biederman J, Wilens T. Attention-deficit/hyperactivity disorder and comorbidity［J］. Pediatr Clin North Am, 1999, 46(5): 915-927.
［3］McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder［J］. J Child Adolesc Psychopharmacol, 2006, 16(3): 351-356.
［4］Kratochvil CJ, Wilens TE, Greenhill LL, Gao H, Baker KD, Feldman PD, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder［J］. J Am Acad Child Adolesc Psychiatry, 2006, 45(8): 919-927.
［5］Weiss M, Tannock R, Kratochvil C, Dunn D, Velez-Borras J, Thomason C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD［J］. J Am Acad Child Adolesc Psychiatry, 2005, 44(7): 647-655.
［6］American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder ［M ］. 4 th ed. Washington DC: American Psychiatric Association, 1994: 129-130.
［7］Gau SS, Shen HY, Soong WT, Gau CS. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attentiondeficit/hyperactivity disorder in Taiwan［J］. J Child Adolesc Psychopharmacol, 2006,16(4): 441-455.
［15］Steele M, Weiss M, Swanson J, Jenny W, Prinzo RS, Binder CE.A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder［J］. Can J Clin Pharmacol, 2006,13(1): 50-62.
［18］Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome［J］. J Atten Disord, 2008,11(4): 470-481.
［19］Allen AJ, Kulan RM, Gibert DL,Coffey BJ, Linder SL, Lewis DW, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders［J］. Neurology, 2005, 65(12): 1941-1949.
［20］Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V,et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder［J］. J Am Acad Child Adolesc Psychiatry, 2007, 46(9): 1119-1127.
